Navigation Links
Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Date:9/18/2009

SAN DIEGO and MIAMI, Sept. 18 /PRNewswire-FirstCall/ -- Sorrento Therapeutics, Inc. ("STI"), a privately-held and development-stage biopharmaceutical company with a proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, has merged with a wholly-owned subsidiary of QuikByte Software, Inc. (OTC Bulletin Board: QBSW), a publicly-traded company with no active operations. As a result of the merger, Sorrento has become a wholly-owned subsidiary of QuikByte. In connection with the consummation of the merger, QuikByte intends to change its name to "Sorrento Therapeutics, Inc." and redomesticate to a corporation incorporated under the laws of the State of Delaware. The combined company will be headquartered in San Diego, California.

Immediately prior to the closing of the merger, QuikByte completed a $2 million private placement of its common stock to certain investors, including affiliates of Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health, Inc. (NYSE Amex: OPK), which was a stockholder of STI prior to the merger, and an affiliate of Mr. Glenn L. Halpryn, a director of QuikByte and its Chairman, President and Chief Executive Officer prior to the merger, and Mr. Steven Jerry Glauser, a greater than 5% shareholder of QuikByte, President of the Glauser Group, Denver, Colorado and President and Managing Partner of Alex Rodriguez Mercedes Benz, Houston, Texas.

Upon the completion of the merger, after giving effect to the private placement, the QuikByte shareholders as of immediately prior to the private placement owned approximately 4.92% of the combined company, the investors in the private placement, some of whom were QuikByte or STI shareholders prior to the private p
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
4. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
5. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
6. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
7. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
8. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
9. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
10. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... of scientific research products, recently opened an online ... comprehensive cell culture product lines developed and manufactured ... its online store include Biological Industries’ Nutristem® serum-free, ... and human embryonic stem cell (hESC) culture. ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... ALTO, Calif., July 8 Telik, Inc.,(Nasdaq: ... in Bioorganic &,Medicinal Chemistry Letters describing a novel ... to a new treatment for diabetes.,These unique compounds ... at Telik to optimize the original lead structure ...
... distribute US-made bulk API, BATON ROUGE, ... Corporation (NYSE: ALB ), a leading ... other active pharmaceutical,ingredients (APIs), has signed a ... Ltd. As per the agreement, effective,immediately, Albemarle ...
... 8 GeneGo, Inc., the leading,systems biology tools ... has become a certified GeneGo Center of Excellence ... training and advanced,support., The W. M. Keck ... largest biotechnology laboratories of its kind in academia, ...
Cached Biology Technology:Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 populations ... the globe dropped 52 percent, says the 2014 ... Fund (WWF). This biodiversity loss occurs disproportionately in ... of high-income countries. , In addition to the ... point to other warning signs about the overall ...
(Date:9/29/2014)... According to a new Food and Brand Lab pilot ... increase participation in the National School Lunch Program (NSLP) ... by 16%! , Chefs Move to Schools (CMTS), an ... with schools in order to provide nutrition instruction to ... workers. , A CMTS event was held in an ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2Half of global wildlife lost, says new WWF report 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... blocks for next-generation computer memory has earned a University ... award. Vassiliy Lubchenko, an assistant professor of ... Alfred P. Sloan Research Fellow for his achievements and ... 54 colleges and universities in the United States and ...
... laboratory research using magnetically guided nanoparticles to deliver drugs ... has just spun off its first startup company, Vascular ... VMI, a new company formed to develop the lab ... to create a novel, greatly needed treatment for peripheral ...
... Obesity appears to impair normal muscle function ... implications for humans, according to Penn State researchers. ... accumulating excess fat and carrying excess weight," said ... in physiological genomics, Penn State College of Medicine. ...
Cached Biology News:UH chemist investigates material for next-generation computer memory 2CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research 2CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research 3Obesity creates wimpy rats 2
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
MarrowMAX Bone Marrow Medium...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: